A Dose Escalation, Safety, Pharmacokinetic, Pharmacodynamic and Preliminary Efficacy Study of SAR650984 (Isatuximab) Administered Intravenously in Combination With Bortezomib - Based Regimens in Adult Patients With Newly Diagnosed Multiple Myeloma Non Eligible for Transplantation

Trial Profile

A Dose Escalation, Safety, Pharmacokinetic, Pharmacodynamic and Preliminary Efficacy Study of SAR650984 (Isatuximab) Administered Intravenously in Combination With Bortezomib - Based Regimens in Adult Patients With Newly Diagnosed Multiple Myeloma Non Eligible for Transplantation

Recruiting
Phase of Trial: Phase I

Latest Information Update: 17 Aug 2017

At a glance

  • Drugs Isatuximab (Primary) ; Bortezomib; Cyclophosphamide; Dexamethasone; Dexamethasone
  • Indications Haematological malignancies
  • Focus Adverse reactions
  • Acronyms CyBorDSAR
  • Sponsors Sanofi
  • Most Recent Events

    • 10 Aug 2017 Planned End Date changed from 18 Sep 2024 to 3 Oct 2024.
    • 10 Aug 2017 Planned primary completion date changed from 18 Sep 2024 to 3 Oct 2024.
    • 09 May 2017 Planned End Date changed from 1 Jun 2024 to 18 Sep 2024.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top